Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 12/23/2020 (updated 4/4/2024)
This technical package provides evidence of the effectiveness of strategies and approaches for supporting successful planning, design, implementation, and sustainability of syringe services programs (SSPs). It provides a broad framework for new and existing SSPs to ensure needs-based service delivery, reduce harms related to injection drug use, and link participants to services that support their health and wellness.
Posted 11/11/2021 (updated 4/3/2024)
Joined this panel of former RCORP-Planning grantees as they shared their lessons learned and how they hit the ground running as they completed Planning and embarked on Implementation. Heard from panelists who received Implementation funding as well as those who were able to move forward without dedicated Implementation funding.
Posted 10/28/2020 (updated 4/3/2024)
In this year 2 kickoff session, HRSA Project Officers will share reminders and updates about grant deliverables, the Evaluation Team will give updates, and Technical Expert Leads will discuss new and ongoing technical assistance available to Implementation I and MAT-Expansion grantees.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 6/7/2022 (updated 3/27/2024)
This session provided information on program updates and the Year 2 Sustainability template due September 2022.
Posted 6/7/2022 (updated 3/27/2024)
This session began with a discussion of the timeline, PIMS, sustainability plan, and no cost extensions with the Implementation I cohort. The Implementation II cohort joined the discussion and information was provided on sustaining change in communities.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).